.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Initial Therapy for Advanced Renal Cell Carcinoma

EP. 1: Biology of Clear Cell Renal Cell Carcinoma

March 31st 2020

EP. 2: Treatment Landscape of Advanced Clear Cell RCC

March 31st 2020

EP. 3: Renal Cell Carcinoma: Early Management Strategies

March 31st 2020

EP. 4: Importance of Risk Assessment in Renal Cell Carcinoma

March 31st 2020

EP. 5: Favorable-Risk RCC: Factors in Selecting Therapy

March 31st 2020

EP. 6: Favorable-Risk RCC: Frontline VEGF TKI/IO Combinations

March 31st 2020

EP. 7: Favorable-Risk RCC: Options for VEGF TKI Monotherapy

March 31st 2020

EP. 8: How to Manage Borderline Intermediate-Risk RCC

March 31st 2020

EP. 9: Treatment Options for Intermediate/Poor-Risk RCC

March 31st 2020

EP. 10: Sequencing Therapies After Progression of RCC

March 31st 2020